Advertisement

Drugs & Therapy Perspectives

, Volume 13, Issue 1, pp 1–4 | Cite as

Brimonidine: a useful new topical treatment for glaucoma and ocular hypertension

New Drugs and Disease Management

Keywords

Glaucoma Timolol Pilocarpine Latanoprost Ocular Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Quigley HA. Open-angle glaucoma. N Engl J Med 1993 Apr; 328(15): 1097–106PubMedCrossRefGoogle Scholar
  2. 2.
    Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998 Mar; 12(3): 225–41PubMedCrossRefGoogle Scholar
  3. 3.
    Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104: 131–6PubMedGoogle Scholar
  4. 4.
    Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: S39–47PubMedCrossRefGoogle Scholar
  5. 5.
    Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: 27–37CrossRefGoogle Scholar
  6. 6.
    Gandolfi SA. The additive effect of brimonidine 0.2% BID compared with pilocarpine 2.0% TID in patients on beta-blocker monotherapy (abstract). Joint European Research Meeting in Ophthalmology and Vision (JERMOV); 1997 Oct 15–19: MontpelierGoogle Scholar
  7. 7.
    Allergan Limited. Alphagan®. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998–99. London: Datapharm Publications Ltd: 54–5Google Scholar
  8. 8.
    Allergan Inc. Brimonidine tartrate. PDR Generics 1998. Montvale (NJ): Medical Economics: 375Google Scholar
  9. 9.
    Abel Jr RS, Abel AD. Ocular diseases. In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland: Adis International Limited, 1997: 581–605Google Scholar
  10. 10.
    Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging 1992 May–Jun; 2: 208–21PubMedCrossRefGoogle Scholar
  11. 11.
    Patel SS, Spencer CM. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996 Nov; 9: 363–78PubMedCrossRefGoogle Scholar
  12. 12.
    Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994 Sep; 5: 156–70PubMedCrossRefGoogle Scholar
  13. 13.
    Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997 May; 10: 384–403PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations